Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis

European Journal of Neurology

Volumn 22, Issue 8, 2015, Pages 1169-1175

  Villar, L M ^a   Picon C ^a   Costa Frossard, L ^a   Alenda, R ^a   Garcia Caldentey J ^a   Espino M ^a   Muriel, A ^a   Alvarez Cermeno J C ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Axonal damage; CSF; Immunological biomarkers; Multiple sclerosis; Neurodegeneration; Neurofilament light chain; Oligoclonal IgM bands

Indexed keywords

BIOLOGICAL MARKER; CD19 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; OLIGOCLONAL BAND;

ADULT; ARTICLE; AXONAL INJURY; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; IMMUNOLOGY; MIDDLE AGED; NERVE FIBER; PATHOLOGY;

ADULT; AXONS; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; OLIGOCLONAL BANDS;

EID: 84935723847     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12579     Document Type: Article

References (35)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
2. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
3. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 327-337.
4. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002; 59: 1565-1571.
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
6. Trapp BD, Peterson J, Ransohoff R, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
7. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-1183.
8. Dutta R, Trapp B. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011; 93: 1-12.
9. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005; 76: 206-211.
10. Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725.
11. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552-556.
12. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19: 1597-1603.
13. Burman J, Zetterberg H, Franssonn M, Loskog ASL, Raininko R, Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand 2014; 130: 81-89.
14. Gunnarsson M, Malmeström C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
15. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75: 116-126.
16. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013; 8: e75091.
17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
18. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
19. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
20. Masjuan J, Álvarez-Cermeño JC, García-Barragán N, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006; 66: 576-578.
21. Villar LM, Roldán E, Masjuan J, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
22. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
23. Malmeström C, Lycke J, Haghighi S, et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 2008; 196: 159-165.
24. Kuenz B, Lutterotti A, Ehling R et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008; 3: e2559.
25. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis clinical course. Brain 1989; 112: 1419-1428.
26. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
27. Leray E, Yaouang J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913.
28. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J 1990; 300: 631-634.
29. Truyen L, van Waesberghe JHTM, van Walderveen MAA, et al. Accumulation of hypointense lesions ('black holes') on T, spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1995; 45: 1684-1690.
30. Pender MP. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? J Clin Neurosci 2004; 1: 689-692.
31. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 19057-19062.
32. Thangarajh M, Gomez-Rial J, Hedström AK, et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008; 14: 1208-1213.
33. Magraner MJ, Boscá I, Simó-Castelló M, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012; 54: 5-12.
34. Sádaba MC, Tzartos J, Paíno C, et al. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 2012; 247: 86-94.
35. Cross AH, Wu GF. Oligoclonal bands still yield clues about multiple sclerosis. Nat Rev Neurol 2010; 6: 588-589.